JP2002542256A5 - - Google Patents

Download PDF

Info

Publication number
JP2002542256A5
JP2002542256A5 JP2000612324A JP2000612324A JP2002542256A5 JP 2002542256 A5 JP2002542256 A5 JP 2002542256A5 JP 2000612324 A JP2000612324 A JP 2000612324A JP 2000612324 A JP2000612324 A JP 2000612324A JP 2002542256 A5 JP2002542256 A5 JP 2002542256A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutically acceptable
acceptable salt
amino
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000612324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2000/003459 external-priority patent/WO2000063234A2/en
Publication of JP2002542256A publication Critical patent/JP2002542256A/ja
Publication of JP2002542256A5 publication Critical patent/JP2002542256A5/ja
Pending legal-status Critical Current

Links

JP2000612324A 1999-04-20 2000-04-17 ピロリジンカルボニルアミノ環状ジスルフィド類 Pending JP2002542256A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13021599P 1999-04-20 1999-04-20
US60/130,215 1999-04-20
PCT/EP2000/003459 WO2000063234A2 (en) 1999-04-20 2000-04-17 Pyrrolidincarbonylamino cyclic disulfides as vcam-vla4 antagonists

Publications (2)

Publication Number Publication Date
JP2002542256A JP2002542256A (ja) 2002-12-10
JP2002542256A5 true JP2002542256A5 (cg-RX-API-DMAC7.html) 2007-06-14

Family

ID=22443611

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000612324A Pending JP2002542256A (ja) 1999-04-20 2000-04-17 ピロリジンカルボニルアミノ環状ジスルフィド類

Country Status (15)

Country Link
US (1) US6265572B1 (cg-RX-API-DMAC7.html)
EP (1) EP1171452B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002542256A (cg-RX-API-DMAC7.html)
KR (1) KR100636481B1 (cg-RX-API-DMAC7.html)
CN (1) CN1167710C (cg-RX-API-DMAC7.html)
AR (1) AR023546A1 (cg-RX-API-DMAC7.html)
AT (1) ATE337331T1 (cg-RX-API-DMAC7.html)
AU (1) AU769294B2 (cg-RX-API-DMAC7.html)
BR (1) BR0009838A (cg-RX-API-DMAC7.html)
CA (1) CA2370259A1 (cg-RX-API-DMAC7.html)
DE (1) DE60030266T2 (cg-RX-API-DMAC7.html)
ES (1) ES2269141T3 (cg-RX-API-DMAC7.html)
TR (1) TR200103004T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000063234A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108018B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939855B2 (en) * 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US20090043126A1 (en) * 2005-02-28 2009-02-12 Jordi Bosch I Llado Process and Methods for the Preparation of Gabapentin and Its Intermediates
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
WO2013057096A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
DK3873884T3 (da) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds

Similar Documents

Publication Publication Date Title
JP2022553994A5 (cg-RX-API-DMAC7.html)
US11021513B2 (en) Peptidomimetics for the treatment of norovirus infection
CN105164117B (zh) 二肽和三肽环氧酮蛋白酶抑制剂
TW202233204A (zh) 用於治療病毒感染之化合物及方法
TWI316942B (en) Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
KR20220026538A (ko) 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
JPH09500120A (ja) 環式ヒドラジン化合物
JP2003506354A5 (cg-RX-API-DMAC7.html)
TW200936131A (en) Macrocyclic serine protease inhibitors
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2013521295A (ja) イムノプロテアソーム阻害のための化合物
JP2009507909A5 (cg-RX-API-DMAC7.html)
JP2008545793A5 (cg-RX-API-DMAC7.html)
US20240277795A1 (en) Inhibitors of cysteine proteases and methods of use thereof
US12630498B2 (en) Arylamides and methods of use thereof
JP2009500423A5 (cg-RX-API-DMAC7.html)
JP2015524394A (ja) ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
US20180369209A1 (en) Methods of treating pulmonary diseases and disorders
JP2023510332A5 (cg-RX-API-DMAC7.html)
JP2011523952A (ja) シクロスポリン類似体及びhcv感染の治療におけるその使用
CN1282336A (zh) 半海盘灵类似物
JP2004529172A5 (cg-RX-API-DMAC7.html)
JP2025515833A5 (cg-RX-API-DMAC7.html)
MXPA06013221A (es) Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonistas enantiomericamente puros.
US20260060926A1 (en) Novel ionizable lipids and lipid nanoparticles and methods of using the same